WAVEMAN · COMPANY

SNYR · Synergy Chc Corp.

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

SNYR

Name: Synergy CHC Corp. (SNYR) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Synergy CHC Corp.

PHARMA & BIOTECH · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · CIK 0001562733

SEC FILINGS☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

-12.8%

XBRL, annual

NET MARGIN

-40.6%

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

no member of Congress has reported trading it

FUNDS

11 funds added or opened last quarter

below 81% of Pharma & Biotech

REVENUE

-12.8% year over year

below 71% of Pharma & Biotech

MARGIN

-40.6% net margin

below 56% of Pharma & Biotech

BUYBACKS

no share repurchases reported

SHORT

no short interest reported

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -95.7%

-95.7%12M

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows 11 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for Synergy CHC Corp. in the period covered. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

Ross Jack

CEO and Chairman

BUY

2025-07-30

100.0

$369

Ross Jack

CEO and Chairman

BUY

2025-07-29

250.0

$915

Ross Jack

CEO and Chairman

BUY

2025-07-25

350.0

$1.4K

Ross Jack

CEO and Chairman

BUY

2025-07-24

300.0

$1.1K

Ross Jack

CEO and Chairman

BUY

2025-07-22

300.0

$1.1K

123 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 118 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

JANE STREET GROUP, LLC

181,648.0 sh

$36.1K

ACT Advisors, LLC.

151,840.0 sh

$30.1K

XTX Topco Ltd

61,270.0 sh

$12.2K

VANGUARD CAPITAL MANAGEMENT LLC

38,909.0 sh

$7.7K

GEODE CAPITAL MANAGEMENT, LLC

32,775.0 sh

$6.5K

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Heartland Value Fund

$709.5K POSITION · AS OF 2026-03-31

0.1%

Fidelity Extended Market Index Fund

$37.4K POSITION · AS OF 2026-02-28

0.0%

VANGUARD EXTENDED MARKET INDEX FUND

$50.2K POSITION · AS OF 2026-03-31

0.0%

Fidelity Nasdaq Composite Index Fund

$6.4K POSITION · AS OF 2026-02-28

0.0%

Fidelity Series Total Market Index Fund

$8.2K POSITION · AS OF 2026-02-28

0.0%

VANGUARD TOTAL STOCK MARKET INDEX FUND

$65.6K POSITION · AS OF 2026-03-31

0.0%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2019-12
REVENUE	$30.4M	$34.8M	$42.8M	$29.4M
GROSS PROFIT	$20.3M	$23.6M	$32.1M	$20.2M
OPERATING INCOME	$-8.5M	$5.8M	$10.8M	$-8.0M
NET INCOME	$-12.3M	$2.1M	$6.3M	$-9.2M
EPS (DILUTED)	-1.27	0.28	0.86	-0.10
OPERATING CASH FLOW	$-2.6M	$-4.8M	$421.7K	$2.9M
CASH	$2.6M	$687.9K	$632.5K	$1.2M
LONG-TERM DEBT	$25.1M	$7.5M	$13.1M	—

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE